5-Ethyl-4,6-dimethylpyrimidine | 1849391-39-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-Ethyl-4,6-dimethylpyrimidine
• CAS: 1849391-39-4
• 化学式: C₈H₁₂N₂
• 分子量: 136.19
• InChiKey: YZPSWCDZBOOMLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS
  申请人：Baroudy Bahige M.

  公开号：US20080188485A1

  公开（公告）日：2008-08-07

  The use of CCR 5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R 1 is hydrogen or alkyl; R 2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroarylalkyl; R 3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R 4 , R 5 and R 7 are hydrogen or alkyl; R 6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  本发明涉及CCR5拮抗剂的使用，其化学式为或其药学上可接受的盐，其中R是可选的取代苯基、吡啶基、噻吩基或萘基；R1是氢或烷基；R2是取代苯基、取代杂环芳基、萘基、芴基、二苯甲基或可选取代的苯基或杂环芳基烷基；R3是氢、烷基、烷氧基烷基、环烷基、环烷基烷基或可选取代的苯基、苯基烷基、萘基、萘基烷基、杂环芳基或杂环芳基烷基；R4、R5和R7是氢或烷基；R6是氢、烷基或烯基；用于治疗HIV、固体器官移植排斥、移植物抗宿主病、关节炎、类风湿性关节炎、炎症性肠病、特应性皮炎、牛皮癣、哮喘、过敏或多发性硬化症，以及新型化合物、包含它们的药物组合物，以及本发明的CCR5拮抗剂与用于治疗HIV或治疗炎症性疾病的抗病毒药物的组合。
• PIPERAZINYLPIPERIDINE DERIVATIVES AS CHEMOKINE RECEPTOR ANTAGONISTS
  申请人：Xue Chu-Biao

  公开号：US20120295912A1

  公开（公告）日：2012-11-22

  The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.

  本发明涉及式I的化合物：其中变量取代基在此定义，可调节或结合于趋化因子受体如CCR5的活性。在某些实施例中，本发明的化合物对CCR5具有选择性。这些化合物可用于治疗与趋化因子受体表达或活性相关的疾病，如炎症性疾病、免疫性疾病和病毒感染。
• SUBSTITUTED 6,6-FUSED NITROGENOUS HETEROCYCLIC COMPOUNDS AND USES THEREOF
  申请人：Genentech, Inc.

  公开号：US20140088076A1

  公开（公告）日：2014-03-27

  The invention provides novel compounds having the general formula: wherein X 1 is N or N + O − , and one of X 2 , X 3 and X 4 is N or N + —O − and the remainder of X 2 , X 3 and X 4 is C. R 2 , R 3 , R 4 , R 5 , R 6 . A, B and Y are as described herein. Additionally compositions compounds of Formula I and methods of use are further described herein.

  该发明提供了具有一般式的新化合物：其中X1是N或N+O−，而X2、X3和X4中的一个是N或N+—O−，而X2、X3和X4的其余部分是C。R2、R3、R4、R5、R6、A、B和Y如本文所述。此外，本文还进一步描述了公式I的组合物化合物和使用方法。
• HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
  申请人：PFIZER INC.

  公开号：US20140336176A1

  公开（公告）日：2014-11-13

  The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.

  本发明提供了部分化合物I的公式： 以及其药学上可接受的盐和上述化合物的N-氧化物；用于制备中间体的制备过程；以及包含此类化合物、盐或N-氧化物的组合物，并且它们用于治疗D1介导（或D1相关）疾病，包括但不限于精神分裂症（例如其认知和消极症状）、认知障碍（例如与精神分裂症、老年痴呆症、帕金森病或药物治疗相关的认知障碍）、注意力缺陷多动障碍、冲动性、强迫性赌博、暴饮暴食、自闭症谱系障碍、轻度认知障碍、与年龄相关的认知衰退、痴呆症、不宁腿综合症、帕金森病、亨廷顿舞蹈症、焦虑症、抑郁症、难治性抑郁症和躁郁症。
• Substituted 6,6-Fused Nitrogenous Heterocyclic Compounds and Uses Thereof
  申请人：Genentech, Inc.

  公开号：US20160060262A1

  公开（公告）日：2016-03-03

  The invention provides novel compounds having the general formula: wherein X 1 is N or N + O − , and one of X 2 , X 3 and X 4 is N or N + —O − and the remainder of X 2 , X 3 and X 4 is C. R 2 , R 3 , R 4 , R 5 , R 6 . A, B and Y are as described herein. Additionally compositions compounds of Formula I and methods of use are further described herein.

  该发明提供了具有一般式的新化合物：其中X1是N或N+O−，而X2、X3和X4中的一个是N或N+—O−，而X2、X3和X4的其余部分是C。 R2、R3、R4、R5、R6、A、B和Y如本文所述。此外，本文还进一步描述了配方I的化合物和使用方法。